An Early Phase 1 interventional study of AB-101 and Placebo in Sexual Dysfunction, Sexual Arousal Disorder and Sexual Dysfunction, Physiological, sponsored by Applied Biology, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-12.
Sponsored by Applied Biology, Inc. · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Sexual Dysfunction, Physiological with a site in United States — 16 open to participants now, 17 under way, none of them phase 3. Sexual Dysfunction, Physiological · United States.
Among the 127 studies in Sexual Dysfunction, Physiological with a site in United States, this one is the 101st largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2018, is one of 2 in phase 1, and was the 83rd registered.
385 studies on the registry are indexed under Sexual Dysfunction, Physiological; 72 are open to participants now.
Browse Sexual Dysfunction, Physiological studies →16 of the 127 studies in Sexual Dysfunction, Physiological with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Women only
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–50 · Women only
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18–45 · Women only
Stanford University · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 46 Sexual Dysfunction, Physiological studies recruiting now, 23 (50%) set no upper age limit and 20 (43%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 16 · Phase 4 13
First in 1998; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 72 across 263 interventional studies indexed under Sexual Dysfunction, Physiological.
Median enrollment 60 across the 107 interventional studies, 98 across the 20 observational. Of the 93 that completed or were terminated, 37 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 127 have an industry lead sponsor. The 10 most frequent:
Applied Biology, Inc. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
Applied Biology, Inc. has 1 study filed under Sexual Dysfunction, Physiological — fewer than ten, so there is no comparison to draw.
3 of the studies in Sexual Dysfunction, Physiological with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768777University of Alabama at BirminghamBehavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis | 2026-12-01 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06059586Indiana UniversityPre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 127 studies in Sexual Dysfunction, Physiological with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
Approximately, 80% of breast cancer survivors undergoing will suffer from a permanent reduced reduction in nipple sensitivity and associated lowerdecrease in sexual quality of life. Currently, there are no treatments for restoring nipple sensitivity and the associatedto improve lower sexual quality of life this condition. It would thus be of great clinical benefit to post breast surgery patients if a provide a new safe and , effective , topical , on-demand, treatment for this condition can be developed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
Drug: AB-101
Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
Drug: Placebo
Apply approximately 1 hour prior to sexual activity
Also known as: Phenylephrine
Apply approximately 1 hour prior to sexual activity
Also known as: Vehicle Solution
Change in Delayed Orgasm Grade
Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0 Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax. This is a binary grading system: Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship
Time frame: [baseline, week 8]
| Milestone | AB-101 | Placebo |
|---|---|---|
| Started | 3 | 0 |
| Completed | 3 | 0 |
| Not completed | 0 | 0 |
Change in Delayed Orgasm Grade (CTCAE v4.0 - Common Terminology of Adverse Events) CTCAE v4.0 is the NIH Common Terminology of Adverse Events v4.0 Delayed Orgasm is defined as: A disorder characterized by sexual dysfunction characterized by a delay in climax. This is a binary grading system: Grade 0:Delay in achieving orgasm not adversely affecting relationship Grade 1:Delay in achieving orgasm adversely affecting relationship
| Grade | AB-101 | Placebo |
|---|---|---|
| Change in Delayed Orgasm Grade | -0.33 ± 0.58 | — |
Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AB-101 | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Placebo | — | — | — |
We were unable to recruit a sufficient number of subjects.
| Age, Categorical(Participants) | AB-101 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 0 | 3 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | AB-101 | Placebo | Total |
|---|---|---|---|
| Female | 3 | 0 | 3 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | AB-101 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | — | 0 |
| Not Hispanic or Latino | 3 | — | 3 |
| Unknown or Not Reported | 0 | — | 0 |
| Region of Enrollment(participants) | AB-101 | Placebo | Total |
|---|---|---|---|
| United States | 3 | — | 3 |
| Delayed Orgasm Grade (CTCAE v4.0)(Grade) | AB-101 | Placebo | Total |
|---|---|---|---|
| Mean | 0.67 ± 0.58 | — | 0.67 ± 0.58 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2018 to primary completion in Oct 2019, 15 months.
Results were first posted in Mar 2020, 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AB-101
Sexual Dysfunction, Physiological →